Arumakimig Biosimilar Bispecific Antibody (IL-18 × IL-1β) for Research

Cat No.: GMP-Bios-INN-1086

Anti-IL18 therapeutic antibody (Pre-made Arumakimig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Arumakimig (development code MAS-825) is a bispecific antibody targeting interleukin-18 and interleukin-1 beta. It is developed by Novartis for autoinflammatory diseases including Still's disease and VEXAS syndrome. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1086-1mg 1mg
GMP-Bios-INN-1086-10mg 10mg
GMP-Bios-INN-1086-100mg 100mg
GMP-Bios-INN-1086-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Arumakimig biosimilar, Bispecific mAb, Anti-IL18;IL1B Antibody: Anti-IL-18/IL18/Interleukin-18/Iboctadekin therapeutic antibody
INN Name Arumakimig
Target IL18;IL1B
Format Bispecific mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1;G1
VD LC Lambda;Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None;None
99% SI Structure None;5bvj:HG:FE:DC:BA/4g6j:HL/4g5z:HL/5bvp:HL
95-98% SI Structure None;None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC